BGM Group advances AI healthcare innovation with $140m AIX Inc. acquisition

BGM Group Ltd. (NASDAQ: BGM), a global biopharmaceutical leader, has taken a pivotal step into artificial intelligence (AI) and insurtech with its acquisition of AIX Inc.‘s intelligent platform. The deal, valued at 1 billion RMB (approximately $140 million), is set to close by the end of 2024 and includes AIX’s subsidiaries, RONS Intelligent Technology (Beijing) Co., Ltd. and Shenzhen Xinbao Investment Management Co., Ltd. This acquisition signals BGM’s strategic move into AI healthcare innovation and its commitment to revolutionizing the industry through intelligent technology integration.

BGM’s strategic entry into digital transformation

The acquisition aligns with BGM Group’s long-term goal of integrating digital transformation strategies into its healthcare operations. Xin Chen, CEO of BGM Group, emphasized the importance of leveraging AIX’s expertise in digital and intelligent systems to drive healthcare industry growth. He highlighted that AIX’s innovations will serve as a foundation for expanding BGM’s global influence, particularly at the intersection of pharmaceutical market expansion and advanced technology.

Chen expressed confidence that the collaboration would enable BGM to deliver more comprehensive and efficient solutions. By incorporating intelligent technology integration into its operations, BGM aims to enhance its offerings for global healthcare and pharmaceutical markets, setting a new standard for innovation.

AIX’s alignment with ai-driven solutions

AIX Inc., a leader in AI applications for the insurance industry, sees this collaboration as an opportunity to expand its platform’s reach and influence. According to AIX’s CEO, Hu Yinan, the partnership with BGM aligns with national policies promoting the silver economy and the development of elderly care technologies. He added that insurance technology solutions will evolve through this synergy, opening avenues for greater innovation in the broader healthcare sector.

RONS Intelligent Technology, a wholly owned subsidiary of AIX, has established itself as a disruptor in the insurtech domain with products like Du Xiaobao and the RONS Open Platform. These solutions have demonstrated strong potential for supporting BGM’s transition into AI-driven healthcare. Meanwhile, Xinbao Investment’s Baowang platform offers over 300 insurance products from 30+ companies, providing comprehensive insurance technology solutions to individuals, families, and small businesses.

Redefining global healthcare transformation

BGM’s acquisition is poised to reshape global healthcare transformation by combining the company’s biopharmaceutical expertise with AIX’s AI-driven platforms. This integration will empower BGM to create a cohesive ecosystem where biopharmaceuticals and insurtech converge, delivering intelligent and connected solutions.

BGM Group, headquartered in Chengdu, China, is renowned for its contributions to biopharmaceuticals, including oxytetracycline APIs, crude heparin sodium, and licorice-based treatments. The company has now positioned itself as a leader in AI healthcare innovation, demonstrating its commitment to redefining the industry landscape.

RONS Intelligent Technology and Xinbao Investment are expected to benefit significantly from BGM’s global market presence. BGM’s extensive pharmaceutical network offers new application opportunities for these subsidiaries, supporting their growth in healthcare and insurance. Together, they plan to explore innovative business models, ensuring sustained profitability and expanding their reach into untapped markets.

A transformative partnership for the future

Industry experts view this acquisition as a game-changing development for both companies. BGM Group’s diversification into intelligent technology and insurtech could serve as a blueprint for other industry players, setting benchmarks in pharmaceutical market expansion and global healthcare transformation.

As the deal progresses toward completion, the collaboration between BGM Group and AIX Inc. is anticipated to drive significant advancements in both sectors. By focusing on AI healthcare innovation and intelligent technology integration, the partnership aims to create value for customers, shareholders, and the global community, while setting the stage for a new era in healthcare and technology.